Purpose: To compare the efficacy and safety of Botox and Neuronox in the management of benign essential blepharospasm (BEB). Methods: We performed a triple-masked, randomized control study to compare Botox and Neuronox in 48 eyes of 24 patients with BEB. All 24 patients randomly received Botox or Neuronox in the periorbital region in a masked, randomized split-face manner, keeping the injection sites and doses uniform. The toxin preparation, injection, and clinical evaluations were done by three independent observers. Objective outcome measures included improvement in the severity of spasm, grading of the functional visual status, changes in palpebral fissure height, lagophthalmos, superficial punctate keratitis and Schirmer's test at 2 weeks, 6 weeks, and upon conclusion of the effect of the toxin. Subjective outcome measures included duration of the effect and a forced choice stating which half of the face was better. Evaluations were performed through clinical measurements, external digital photography, and high-definition videography. Results: The mean duration of relief from spasms was 3.78 months (standard deviation, 1.58 months; range, 1 to 6 months). The improvement in the objective parameters like severity of spasm and functional visual status was statistically significant at the 2-week and 6-week follow-up visits (p < 0.001). The changes in palpebral fissure height, lagophthalmos, and superficial punctate keratitis were equally observed in both groups. At 2 and 6 weeks, three of 24 (12.5%) and one of 24 (4%) patients, respectively, reported an unequal effect between the two sides of the face, but this difference was not statistically significant. At final follow-up (conclusion of the toxin effect), patients reported equal effect with no preference for either hemiface. No statistically significant differences were found in the comparative analysis between the Neuronox and Botox groups. Conclusions: Neuronox and Botox are comparable in terms of their safety and efficacy in the management of BEB.
Slough,UK) [1] [2] [3] ,Xeomin(MerzPharmaceuticals,Frank-furtamMain,Germany),andProsigne(LanzhouBiologi-calProducts,Lanzhou,China) [4, 5] .Neuronox(Medytox, Seoul,Korea)isarecentlyintroducedBTX-Apreparation. BotoxandNeuronoxarepurifiedextractsofBTXtypeA availableasvacuum-driedandafreeze-driedlyophilized preparations,respectively [6, 7] .Thoughbothproductsare nearlysimilar,Neuronoxischeaper.Thishasabearingon thechoiceoftheproduct,especiallyforarepetitivedisor-derlikeBEB.
Thereareverylimiteddatacomparingthetwoproducts. Stoneetal. [8] studiedthedose-responserelationshipfor inhibitionofmuscleforceofBotoxandNeuronoxinamurinemodelandcharacterizedthetimecourseofrecovery fromthetoxin-inducedmuscleparalysis.Gastrocnemius muscleforcegenerationwasexaminedfollowingstimulationof the tibial nerve. Botoxand Neuronox produced nearly equivalent decrements in muscle force (30% to 90%)at4daysaftertoxininjection.At28daysafterinjection(1U/kg),muscleforcehadrecoveredfromtheeffects of bothtoxin preparations.Forfacialspasms,onlyone double-blind,prospective,randomizedcontrolstudyhas beenconductedinhumanstocompareBotoxand Neu-ronoxintwoseparatecohortsofBEBpatientsinKorea [9] . Thestudyconcludedthatbothpreparationsarecomparableintermsoftheirsafetyandefficacy.However,more studiesareneededtoconsolidatethecomparativedata.
Wethereforeutilizedthebilaterallysymmetricalnature ofBEBtoconductasplit-face,prospective,randomized controlstudytocomparesafetyandefficacyofthetwo BTX-ApreparationsinthemanagementofBEB.Asplit facestudyeliminatesanyconfoundingfactorsthatmight beatplaywhentwoseparatecohortsarestudied.
Materials and Methods
Thissplit-face prospective randomizedcontrolstudy wasconductedinaccordancewiththeprinciplesofthe declarationofHelsinki.Thestudyprotocolaswellaspatient consent were approved by the institution review boardofLVPrasadEyeInstitute,Hyderabad,India(LEC 11-067).Allpatientsconsentedtoparticipationinthestudy beforeenrollment.Thestudy wasconductedat theLV PrasadEyeInstitute,Hyderabad,India.Allpatientsdiag-nosedwithBEBandfulfillingtheinclusionandexclusion criteria(Table1)wereincludedinthissplit-facestudy.
Sincetherewasnopriorsplit-facestudytocomparethe twodrugs,wedecidedtoperformthisasapilotstudyen-rollingaminimumof20patients.EachvialofBotoxor Neuronoxcontained100units(U)ofClostridium Botuli-numtypeAneurotoxincomplex,0.5mgofhumanalbumin,and0.9mgofsodiumchlorideinasterile,driedsolid withoutpreservatives.Each100-Uvialwascarefullyre-constitutedwith4mLofsterile,non-preserved0.9%nor-malsalinetoachieveaconcentrationof2.5U/0.1mL.The reconstitutedsolutionwasstoredinarefrigeratorat4°C untilneeded.A30-gaugehalf-inchneedlewasusedforall 
Pre-injection phase
Writteninformedconsentwasobtainedfromtheappropriatelyincludedparticipants.Severityofspasmandfunctionalvisualstatusweregradedusingthementionedgrading system ( Table 2 ). The grading was done at the pre-injection visit and atsubsequentfollow-up assessments. Palpebral f issure height, lagophthalmos, and Schirmer'stestwithouttopicalanaestheticweredocumentedatthepre-injectionvisitandatsubsequentfollow-up visits.Digitalexternalphotographsoftheupperhalfofthe faceandahigh-definitionvideoclipwererecordedtofurtherdocumentthemeasuredparameters.
Injection phase
Theinjectorwasprovidedwithtwoidenticalsyringes containingequalamountsoftoxin.Tomasktheidentityof thetoxinfromtheinjectorandthepatient,thesyringes werelabeledasdrugAanddrugB.Thesesyringeswere loadedandprovidedtotheinjectorbyasingleobserver (MJA)whowasblindedtotheinjectiontechniquesandthe post-injectionevaluations.Therightsideofthefacewas injectedfirstwitheitherdrugAordrugB,selectedrandomlybysecretballotmethod.Anequaldoseofthere-mainingdrugwasinjectedontheleftside.Allpatientsre-ceived17.5to20Uofagivendrugoneachhalfsideofthe face.Theidentityofthedrugs(drugsAandB)wasconcealeduntiltheendofthestatisticalanalysis.Astandard techniquewasemployedbyasingleinjector(MNN)toin-ject0.1mLaliquots(2.5U)persitewitha30-gaugeneedle overaTuberculinsyringeatsevenprefixedsitesinthe periorbitalarea( Fig.1 ).Thesiteswereidenticalonboth sides.Thepatientswereprescribedpreservative-freelubricanteyedropsinbotheyes.
Post-injection follow-up phase
Atthe2-and6-weekpost-injectionfollow-upvisits,all theaforementionedclinicalparametersweredocumented. Patientswereencouragedtocomplywithfollow-upvisits bytelephonicreminders.Objectiveoutcomemeasuresincludedimprovementinthegradesofseverityofspasmand functionalvisualscale,aswellastheoccurrenceofside effectslikeptosis,lagophthalmos,andsuperficialpunctuatekeratitis.
Subjectiveoutcomemeasuresincludeddurationofsymptomaticrelief,andasubjectivefeelingofa'better'effect betweenthetwosidesoftheface.Toassessthelatter,the patientwasaskedtochoosewhichside(rightorleft)felt betterthantheother.Photographicandvideographicdocumentationwasobtainedateachfollow-upvisit.Allthe pre-andpost-injectionquestionnairesandevaluationswere performedbyasinglemaskedobserver(SS). Beyondthe6-weekfollow-upvisit,patientswereasked toreportwhentheactionofthetoxinworeoff,andthey felttheneedforthenextinjection.Thepatientwasasked toreportthesubjectivedurationoftheeffectaftercompletewashoutoftheactionofthetoxin,aswellasanyinequalityintheeffectbetweenthetwosidesoftheface.
StatisticalanalysiswasperformedusingtheSPSSver. 16.0(SPSSInc.,Chicago,IL,USA).Forpre-andpost-injectionanalysis,thepairedt-testwasused.Forcomparativeanalysis betweendrugAanddrugB,independent t-testswereused.
Results
Twenty-fourpatientswereenrolledinthisprospective study.Fifteenweremales,andninefemales.Themeanage was52years(SD,11.1years).Theanalysisofparameters such asseverity ofspasm, functional visualscale and forcedchoiceofthebettersidewasdoneconsideringthe totalnumberofpatientsasadenominator(n=24)while forallotherparameters,thedenominatorwastakenasthe totalnumberofeyes(n=48).
Themostcommonpresentationwasinvoluntaryclosure oftheeyesand/orincreasedrateofblinkingnotedinall patients.Twooutof24patientsalsohadspasmodiccon-tractionsofthelowerfaceandneckregion(lowerfacial dystonia),suggestiveofMeigesyndrome.Themeandura-tionofthesymptomswas24.7months.
Twenty-onepatientsreceived17.5Uofthedrugoneach side(total35U),andthreepatientsreceived20U(total40 U).Theidentityofthedrugwasdisclosedonlyafterthe statisticalanalysiswascompleted.DrugAwasrevealedto beNeuronoxanddrugBwasBotox.
Fiveeyeshadlagophthalmosrangingfrom1to3mm, andeighteyeshadsuperficialpunctuatekeratopathy.
Amongtheobjectiveoutcomemeasures,theseverityof spasmandthefunctionalvisualstatusshowedstatistically significantimprovement(Table3).Individualobjective outcomemeasureslikepalpebralfissureheight,induced lagophthalmos,andSchirmerstestshowedstatisticallysignificantdifferences,buttheresultswerecomparableinthe NeuronoxandBotoxgroups(Table4).
Atthe2-and6-weekfollow-up,thedifferenceinoccurrenceofsuperficialpunctatekeratopathywasnotstatisticallysignificantinanyofthegroups.
Amongthesubjectiveoutcomemeasures,themeandu-rationofthesymptomaticreliefwas3.8months(SD,1.6 months;range,1to6months).Atthe2-weekpost-injection follow-up,allthepatientsshowedsymptomaticimprovement.Atthe2-weekvisit,threeoutof24(12.5%;95%CI, 0to25.7)patientsnotedthattheeffectofthetreatment wasbetterononesidecomparedtotheother,wherethe bettersidehadreceivedNeuronox.Atthe6-weekvisit,one patient(4%)reportedmoreactivityononehalfoftheface comparedtotheother,wherethebettersidehadreceived Botox.Thesedifferencesintheirforcedchoiceat2and6 weekswerenotstatisticallysignificant.
Whenaskedtomakeaforcedchoicebetweenthetwo sidesaboutthebenefitandthedurationoftheeffect,all24 patientsfeltthattheeffectofthetreatmentwassimilaron bothsidesoftheface.
Discussion
BotulinumtoxintypeAiswidelyusedinseveralspecialtiesofmedicine.Itisusedasthefirst-linetreatmentin the management of BEB. Botox is the oldest BTX-A preparation,andhenceistime-testedandefficaciousinthe managementofBEB.Neuronoxisarecentlyintroduced BTX-Apreparation,andisstructurallysimilartoBotox. Themeanincreaseinpalpebralfissureheight,lagoph- 
